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INTRODUCTION
Multiple myeloma (MM) is the most common malignancy of plasma cells and accounts for about 1% of all malignant diseases and 10% of haematological malignancies (Lokhorst et al., 2002) . 60-100 MM cases are diagnosed in Latvia yearly (Pildava, 2012) .
Strong CD56-positivity in plasma cells (PC) of some patients with MM, in contrast to normal plasma cells that are mostly CD56-negative in others with MM, has been known since the 1990. However, recent studies of CD56 expression are contradictory. Aberrant CD56 expression has been demonstrated in 70% to 80% of MM cases at diagnosis (Harada et al., 1993; Harrington et al., 2009) . Absence of CD56 expression in MM patients is associated with more aggressive disease and shorter overall survival (Rawstron et al., 1999; Hundemer et al., 2007; Sahara et al., 2009) . Some studies have demonstrated a correlation between CD56-negative myeloma and bone lesions (Chang et al., 2006) . Other authors have not found a significant correlation between CD56 expression and clinical parameters and overall survival (Dunphy et al., 2007) .
Cyclin D1 is a product of the CCND1 gene and in association with cyclin-dependent kinases controls proliferation of PROCEEDINGS OF THE LATVIAN ACADEMY OF SCIENCES. Section B Vol. 72 (2018) , No. 5 (716) eukaryotic cells at specific points in G1, S, G2 phases. (Hitomi et al., 1999; Alt et al., 2000; De Falco et al., 2004; Padhi et al., 2013) . Aberrant expression of Cyclin D1 in MM is associated with genetic abnormalities like translocation t (11;14)(q13;q32), polysomy for chromosome 11, amplification of CCND1 and other genetic abnormalities; this feature is associated with longer overall survival (Hitomi et al., 1999; Cook et al., 2006; Padhi et al., 2013) . Immunohistochemically detected Cyclin D1 protein expression in myeloma cells has been reported in 24-50% cases; some researchers consider that it might provide clinically useful prognostic information (Markovic et al., 2004; Cook et al., 2006; Padhi et al., 2013) . Athanasiou et al. described a correlation between Cyclin D1 overexpression in MM and higher histological grade with favourable prognosis. These patients had a significantly lower level of haemoglobin (Athanasiou et al., 2001) . However, there are studies that have not demonstrated any correlation between Cyclin D1 expression and clinical prognostic parameters (Markovic et al., 2004; Dunphy et al., 2007; Padhi et al., 2013) . p53 protein is a TP53 gene product, which has a crucial role in cell death and can be observed when cells undergo apoptosis in response to oncogenic stimuli. Normally, the cell cycle of cells with damaged DNA is arrested at G 1 -S checkpoint until the damage is repaired, but cells that lack p53 or contain a mutant form are not arrested at G 1 . Loss or mutation of TP53 is probably the most common single genetic change in malignancies when cells do not undergo apoptosis and so escape the control. Tumours that have not lost TP53 very often have mutated versions of it (Strachan et al., 1999; Soussi et al., 2010) . MM patients with aberrant p53 nuclear expression usually are diagnosed in advanced clinical and histological stages, as well as have significantly shorter overall survival than patients without this abnormality. del(17p13) (TP53) and p53 immunohistochemical expression are strongly correlated (Chang et al., 2007; Souss et al., 2010; Chen et al., 2012) .
Of course, overall survival of MM patients depends not only on the stage of MM, but also on different methods of chemotherapy (Soverini et al., 2003; Markovic et al., 2004; Lonial et al., 2016) and concomitant diseases. Some clinical and serological findings like osteolitic changes, glomerular filtration rate (GFR), level of ß2-microglobulin, M-protein, haemoglobin, calcium, albumin, creatinine etc. are useful for detection of MM stage and prognosis (Sailer et al., 1995; Goldschmidt, et al., 2001; Greipp et al., 2005) . From 2005, the International Staging System for Multiple Myeloma has been used for MM staging, and the Salmon-Durie clinical staging system has been applied accordingly for the Classification of Multiple Myeloma (Greipp et al., 2005) .
The aim of our study was to evaluate CD56, Cyclin D1, p53 expression in bone marrow tissue and its correlation with clinical and biochemical prognostic parameters of MM cases.
Our study is the first in European and Baltic countries that is based on the analyses of 122 patients. We found statistical correlation between more than 10 clinical and biochemical markers and expression of CD 56, p53, and Cyclin D1 in myeloma cells of bone morrow. These data will be used as predictive indicators of progression of multiple myeloma.
MATERIALS AND METHODS
Study population. Bone marrow biopsies of 122 patients from Rîga East Clinical University Hospital's Haematology Centre with MM diagnosed between 2011 and 2015 were enrolled in the study. Our study was designed in conformation to the Helsinki Declaration. The study protocol was approved by the Committee of Ethics, Rîga Stradiòð University.
Immunohistochemistry. Bone marrow biopsies were fixed in 10% neutral (pH = 7) buffered formalin solution, decalcified in "MicroDecfast" decalcification solution (Diapath, Italy), processed in "Sakura Tissue-Tek VIP 5" vacuum infiltration tissue processor and embedded in paraffin. All bone marrow biopsies were stained with routine haematoxylin and eosin, Periodic acid-Schiff (PAS), Giemsa stain and Gordon and Sweet's reticulin silver staining method using standard protocols (Bio-optica, Italy).
Immunohistochemical antigen expression was determined by a standard polymer based visualisation system (EnVision method by Dako/Agilen, Denmark/U.S.A.).
4-5-µm thick formalin fixed paraffin-embedded bone marrow biopsies were placed on adhesive positively charged slides. After de-waxing and rehydration, through alcohols to water, the slides were incubated with 3% H 2 0 2 for 10 minutes to inhibit endogenous peroxidase activity. The microwave-based antigen retrieval was performed in a freshly prepared 0.01 mol/l sodium citrate buffer (pH 6.0) solution at 750 W for 3 cycles, 10 minutes each.
Samples were immunostained using primary antibodies: Cyclin D1 (Clone-SP4, Ready-to-Use, Dako), p53 (CloneDo-7, Ready-to-Use, Dako) and CD56 (Clone-123C3, at a 1 : 50 dilution, Dako) and 3.3?-diaminobenzidine-tetrahydrochloride dihydrate (DAB) as the chromogen (DAKO, Denmark). Slides were counterstained with Mayer's haematoxylin, dehydrated in alcohol, cleared in xylene and cover slipped.
Cyclin D1, p53, and CD56 expression in cytoplasm of myeloma cells was considered positive if more than 10% cells were stained with strong positive reaction, but considered negative if less than 10% of the cells were stained. We evaluated correlation between histological findings and patients' clinical data -gender, age, osteolytic lesion, laboratory data and stage by Classification of Multiple Myeloma according to the Salmon-Durie clinical staging system and the International Staging System (Durie and Salmon, 1975; Greipp et al., 2005) for MM.
Surgery material of five patients with nonspecific spondylitis was used as control. These samples were characterised as having prominent polyclonal plasmocytosis without atypical changes.
All slides were examined and photographed with a Leica Microscope (Leitz, Wetzlar, Germany).
Clinical-laboratory data. Normal levels of the studied clinical-laboratory parameters are shown in brackets: ß2-microglobulin (0-3 mg/l), albumin (34-52 g/l); haemoglobin (male: 126-175 g/l female 118-161 g/l, platelet count (150-410 × 10· 9 l), glomerular filtration rate-GFR (90 2) and also lower platelet count, in comparison to the CD56-positive group. CD56-negative patients were predominately at an advanced Salmon-Durie disease stage and had signifi- ns, not significant, p > 0.05) GFR, glomerular filtration rate cantly higher ß2-microglobulin and serum creatinine (Fig. 2 ) levels, when compared to the CD56-positive group (p < 0.05). Patient gender, age, the level of LDH, albumin, CRP, calcium, and M-protein did not show any statistically significant differences between CD56-positive and negative groups (Table 2) .
Cyclin D1 antigen expression in plasma cells. Cyclin D1 protein expression (Fig. 3) was detected in 62 (51%) cases. Positive correlation (Table 1) was observed between cyclin D1 expression and Salmon-Durie clinical stage, calcium, ß2-microglobulin level and osteolytic lesion in bones (p < 0.05). The patient group with positive Cyclin D1 expression in PCs (Table 3) had significantly higher ß2-microglobulin (p = 0.034) and calcium (p = 0.0096) levels, compared to those in the Cyclin D1 negative group (Fig. 4) . The Cyclin D1 positive patient group had a more advanced SalmonDurie stage and had significantly more pronounced bone osteolitic lesions, compared these parameters for the Cyclin D1 negative patient group (p < 0.05).
p53 antigen expression in plasma cells of MM patients.
p53 protein was detected in 44 (36%) cases (Fig. 5) . Significant positive correlation (p < 0.05) was observed between p53 protein expression in plasma cells (Table 1) and Salmon-Durie MM clinical stage, ß2-microglobulin and serum creatinine level. Furthermore, significant negative cor- relation was observed between p53 expression and haemoglobin level, glomerular filtration rate and thrombocyte count. The p53-positive group (Table 4) had a more advanced Salmon-Durie MM stage (p < 0.0001), significantly higher ß2-microglobulin (p = 0.029), serum creatinine (p = 0.0192) levels, compared these parameters in the p53-negative group (Fig. 6 ).
The p53-positive group had a significantly lower haemoglobin level (p < 0.0001) and platelet count (p = 0.0188) than in the p53-negative group. In addition, the p53-positive group had a lower GFR (Fig. 6 ), compared to that in the p53-negative group (p = 0.0215).
DISCUSSION
Histological examination combined with immunohistochemistry plays an important role in MM management. Besides being the gold standard for diagnosis, it provides prognostic information such as degree of bone marrow infil- tration, grade of tumour cell atypia and immunophenotype. Experimental treatment based on immunohistochemical findings was recently introduced for refractory MM, for example, by stimulation of p53-related apoptosis and antibody based treatment with anti-CD56 drugs (Soverini et al., 2003; Teoh et al., 2014; Lonial et al., 2016) . The current tendency of individually tailored treatment implies that in the future, the immunophenotype of each MM patient will have to be taken into consideration, since genetic and immunohistochemical characteristics are very heterogeneous.
In the current study, we retrospectively analysed prognostic plasma cell antigenic biomarkers (Cyclin D1, CD56, p53) in 122 trephine bone marrow biopsies and evaluated their relation to serological, clinical and laboratory parameters in a large cohort of primary MM patients.
Several markers, like ß2-microglobulin, haemoglobin, and albumin levels have been proposed as prognostic factors in MM. It is also known that overall survival of MM patients is correlated with the creatinine level and GFR (Durie and Salmon, 1975; Greipp et al., 1988; Hartmut et al., 2001; Greipp et al., 2005) . Since previous studies (Sailer et al., 1995; Greipp et al., 2005; Lonial et al., 2016) demonstrated prognostic significance of the immunohistochemically detected phenotype of tumour cells in MM, new data on relations between biochemical and histological prognostic markers could be of particular interest.
We detected an aberrant CD56 expression in myeloma cells in 78% of cases, using immunohistochemical method. According to literature data, patients that are CD56-negative (detected by flow cytometry) have poorer prognosis (Hague et al., 1994; Korsrneyer et al., 1992) . Our CD56-positive group presented at late Salmon-Durie clinical stage, with a high ß2-microglobulin level, low haemoglobin level, low platelet count and renal insufficiency and was thus was associated with clinical and laboratory markers of poorer prognosis. Clinical follow-up with overall survival assessment seems to be required to resolve the contradiction.
Cyclin D1 is another immunochistochemical prognostic marker associated with genetic abnormalities. Cyclin D1 is necessary for the coordination of the cell cycle G1 / S transition, as cyclins act as regulators of cyclin dependent kinases and have a role in tumourogenesis. Some studies have shown it to have positive prognostic value (Markovic et al., 2004; Cook et al., 2006; Padhi et al., 2013) . In our study we detected Cyclin D1 protein expression in 51% of cases, and it was associated with poorer prognostic indicators, like high ß2-microglobulin and calcium levels. In our analysed group of patients with Cyclin D1 overexpression there were more osteolytic lesions.
p53 was detected in 36% of examined cases using the immunohistochemical method. p53 overexpression was correlated with shorter overall survival. p53 plays a role in apoptosis (Chang et al., 2007; Souss et al., 2010; Chen et al., 2012) . In our study, p53 expression in myeloma cells within a group of patients was also correlated with many prognostic clinical and laboratory findings, such as a high ß2-microglobulin level, late stage according to the SalmonDurie classification, low haemoglobin level, platelet count and renal insufficiency indicated by a decreased GFR and elevated creatinine level.
We have found that overexpression of CD56, Cyclin D1 and p53 in myeloma plasma cells showed a statistically sig-nificant correlation with various clinical and laboratory characteristics of MM. Positivity for p53 and Cyclin D1 and lack of CD56 antigen in myeloma plasma cells are negative predictive factors in MM, associated with an advanced Salmon-Durie stage and higher ß2-microglobulin levels. Chronic renal failure progression, which was also associated with poorer prognosis in MM patients was related to expression of p53 and lack of CD56 antigen in neoplastic plasma cells, as in these patients there was an increased creatinine level in blood and decreased GFR.
Many studies have evaluated Cyclin D1 as a factor of favourable prognosis and indicator of longer survival time in patients treated with standard and new generation medicine.
There are studies about Cyclin D1 levels and it's correlations with clinical and laboratory data. In our study, Cyclin D1 overexpression was more typical for a graver SalmonDurie stage and higher ß2-microglobulin level, thus showing progression of MM.
It is possible that patients with Cyclin D1 antigen expression in myeloma cells may have had improved responsiveness to chemotherapy treatment, which may explain the higher survival rate in previously published studies (Markovic et al., 2004; Cook et al., 2006; Padhi et al., 2013) .
Statistical analysis of our study results showed that expression of Cyclin D1 was not correlated with the indicators of renal function and that these patients did not develop chronic renal failure, one of the most common complications of MM.
Thus, CD56, Cyclin D1 and p53 overexpression can be used for making more precise morphological staging of MM and can be applied as a predictive factor for indicating a more aggressive therapy regimen. CONCLUSIONS 1. Expression of p53 and Cyclin D1, but lack of CD56 antigen in plasma cells, is a negative predictive factor in cases of MM, as late Salmon-Durie stage and higher ß2-microglobulin level are more common in these cases.
2. Expression of p53 and lack of CD56 antigen is associated with paraprotein hyperproduction in plasma cells, which in turn damages renal parenchyma and affects renal function and is associated with an increased creatinine level in blood and decreased GFR.
These correlations are criteria for chronic renal failure progression and poorer prognosis of multiple myeloma patients.
